Novo Nordisk, Insulet and Mayo Clinic helped the diabetes monitoring technology provider push its overall funding past $100m.
US-based patient monitoring technology developer Glooko received $30m in series D funding yesterday from investors including drug producer Novo Nordisk, diabetes equipment provider Insulet and medical research and care provider Mayo Clinic.
Investment manager Health Catalyst Capital led the round, which also featured venture capital firm Canaan and growth equity firm Georgian.
Glooko combines telehealth technology and data sourced from a range of medical devices such as blood-glucose meters, insulin pumps and activity trackers to remotely connect diabetes patients with…
